SMHI's net loss exploded 739% to $78.1M despite revenue surging 264% and achieving operational profitability, indicating severe non-operating financial distress.
The dramatic disconnect between operational improvement (turning $10.4M operating loss into $13.7M operating income) and massive net loss deterioration suggests significant financial leverage issues, with interest expense rising 26% to $37.5M. The company appears to be in a capital-intensive growth phase with capex surging 569% to $48.8M, but the financial structure may be unsustainable given the severe cash flow deterioration.
SMHI shows a tale of two stories - operational recovery with revenue up 264% and swing to operating profitability, but catastrophic bottom-line performance with net losses expanding 739% due to heavy interest burden and non-operating costs. The company is in heavy investment mode with capex up 569% and operating cash flow deteriorating significantly to -$36.4M, suggesting either aggressive expansion or distressed capital allocation that investors should scrutinize carefully.
Net income declined 738.8% — review whether driven by operations, interest costs, or non-recurring items.
Capital expenditure jumped 568.8% — major investment cycle underway; assess returns on deployment.
Strong top-line growth of 263.5% — accelerating demand or successful expansion into new markets.
Operating cash flow fell 254.7% — earnings quality concerns; investigate working capital changes and non-cash items.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Deposits declined 80% — significant outflows warrant immediate investigation into funding stability.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Interest costs rose 26.3% — monitor debt levels and coverage ratio in rising rate environment.
Inventory reduced 20.4% — lean inventory management or demand outpacing supply.
Current liabilities reduced — improved short-term financial position and working capital health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →